Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.54 |
| ▸ | ITGAV | P06756 | 7/20 | 0.54 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.54 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.54 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.51 |
| ▸ | MC4R | P32245 | 9/20 | 0.49 |
| ▸ | MC5R | P33032 | 9/20 | 0.49 |
| ▸ | MC3R | P41968 | 9/20 | 0.49 |
| ▸ | MC1R | Q01726 | 9/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7746248 | 1.00 | ITGB3 (0.54) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL8365144 | 0.97 | ITGB3 (0.53) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL14585819 | 0.96 | MC4R (0.52) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL20888358 | 0.89 | ITGB3 (0.58) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL19605458 | 0.89 | ITGB3 (0.58) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL21766911 | 0.89 | ITGB3 (0.58) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL24253307 | 0.88 | ITGB3 (0.57) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL19605457 | 0.88 | ITGB3 (0.57) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL19605483 | 0.88 | ITGB3 (0.57) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL8365134 | 0.88 | ITGB3 (0.48) | ITGB3ITGAVITGB1ITGA5ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6537520-B1 | Diagnosis and treatment of cancer; kit containing compound having peptide or peptidomimetic functionality that binds to a alpha v beta 3 receptor linked to a chelator | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-03-25 | — | — | US | disclosed |